All In Biotech

Drugs by condition

Drugs approved for melanoma

Brand-name prescription drugs and biologics whose FDA label lists melanoma as an approved use. Matched on the label phrases: "melanoma".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

21

Still marketed, NDA or BLA

Drug classes

7

Novel drugs

15

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for melanoma.

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
  • Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
  • Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) · Genentech INC Sep 12, 2024
  • Hepzato (Melphalan Hydrochloride) · Delcath Systems INC OrphanAug 14, 2023
  • Mekinist (Trametinib, Trametinib Dimethyl Sulfoxide) · Novartis Priority reviewOrphanMar 16, 2023

All approved drugs for melanoma, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 4 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Programmed Death Receptor-1 Blocking Antibody (5)

  • Opdualag Nivolumab, Relatlimab-Rmbw · Bristol Myers Squibb · 2022
  • Tecentriq Atezolizumab · Genentech INC · 2016
  • Opdivo Nivolumab · Bristol Myers Squibb · 2014
  • Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
  • Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024

Endoglycosidase (2)

  • Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
  • Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024

Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager (1)

  • Kimmtrak Tebentafusp-Tebn · Immunocore LTD · 2022

Kinase Inhibitor (1)

  • Zelboraf Vemurafenib · Hoffmann La Roche · 2011

CTLA-4-directed Blocking Antibody (1)

  • Yervoy Ipilimumab · Bristol Myers Squibb · 2011

Lymphocyte Growth Factor (1)

Class not listed in FDA's data (10)

  • Braftovi Encorafenib · Array Biopharma INC · 2018
  • Mektovi Binimetinib · Array Biopharma INC · 2018
  • Cotellic Cobimetinib Fumarate · Genentech INC · 2015
  • Tafinlar Dabrafenib Mesylate · Novartis · 2013
  • Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
  • Lymphoseek Kit Technetium Tc-99m Tilmanocept · Cardinal Health 414 · 2013
  • Hepzato Melphalan Hydrochloride · Delcath Systems INC · 2023
  • Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
  • Tafinlar Dabrafenib Mesylate · Novartis · 2023
  • An-Sulfur Colloid Technetium Tc-99m Sulfur Colloid Kit · Sun Pharm Inds INC · 1978

Drugs in development for melanoma

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • TucidinostatChidamide, HBI-8000Phase 39 trials

    Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

  • IBI363Phase 37 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer

  • OH2Phase 36 trials

    Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer

  • PucotenlimabHX008Phase 36 trials

    Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma

  • CeralasertibAZD6738Phase 35 trials

    AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer

  • DarovasertibIDE 196, LXS196Phase 35 trials

    IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • rHuPH20Phase 35 trials

    Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma

  • AtebimetinibIMM-1-104, Group APhase 34 trials

    Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)

  • GimistotugBGB-A445Phase 34 trials

    BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma

  • EIK1001Phase 33 trials

    Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)

  • IO102-IO103Phase 33 trials

    IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma

  • ABP 206Phase 32 trials

    Amgen · Melanoma

More on melanoma: recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.